These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34831159)
1. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma. Van Loenhout J; Freire Boullosa L; Quatannens D; De Waele J; Merlin C; Lambrechts H; Lau HW; Hermans C; Lin A; Lardon F; Peeters M; Bogaerts A; Smits E; Deben C Cells; 2021 Oct; 10(11):. PubMed ID: 34831159 [TBL] [Abstract][Full Text] [Related]
2. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer. Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801 [TBL] [Abstract][Full Text] [Related]
3. Menadione Potentiates Auranofin-Induced Glioblastoma Cell Death. Szeliga M; Rola R Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555352 [TBL] [Abstract][Full Text] [Related]
4. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells. Kato I; Kasukabe T; Kumakura S Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449 [TBL] [Abstract][Full Text] [Related]
5. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers. Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917 [TBL] [Abstract][Full Text] [Related]
6. Morin enhances auranofin anticancer activity by up-regulation of DR4 and DR5 and modulation of Bcl-2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells. Hwang-Bo H; Lee WS; Nagappan A; Kim HJ; Panchanathan R; Park C; Chang SH; Kim ND; Leem SH; Chang YC; Kwon TK; Cheong JH; Kim GS; Jung JM; Shin SC; Hong SC; Choi YH Phytother Res; 2019 May; 33(5):1384-1393. PubMed ID: 30887612 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T Cell Death Dis; 2014 Apr; 5(4):e1191. PubMed ID: 24763048 [TBL] [Abstract][Full Text] [Related]
8. Altered antioxidant system stimulates dielectric barrier discharge plasma-induced cell death for solid tumor cell treatment. Kaushik NK; Kaushik N; Park D; Choi EH PLoS One; 2014; 9(7):e103349. PubMed ID: 25068311 [TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation. Radenkovic F; Holland O; Vanderlelie JJ; Perkins AV Biochem Pharmacol; 2017 Dec; 146():42-52. PubMed ID: 28947276 [TBL] [Abstract][Full Text] [Related]
10. Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death. Habermann KJ; Grünewald L; van Wijk S; Fulda S Cell Death Dis; 2017 Oct; 8(10):e3067. PubMed ID: 28981107 [TBL] [Abstract][Full Text] [Related]
11. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species. Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer. Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219 [TBL] [Abstract][Full Text] [Related]
13. Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer. Oh BM; Lee SJ; Cho HJ; Park YS; Kim JT; Yoon SR; Lee SC; Lim JS; Kim BY; Choe YK; Lee HG Cell Death Dis; 2017 Mar; 8(3):e2682. PubMed ID: 28300829 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase. Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042 [TBL] [Abstract][Full Text] [Related]
15. Roles of intracellular and extracellular ROS formation in apoptosis induced by cold atmospheric helium plasma and X-irradiation in the presence of sulfasalazine. Moniruzzaman R; Rehman MU; Zhao QL; Jawaid P; Mitsuhashi Y; Imaue S; Fujiwara K; Ogawa R; Tomihara K; Saitoh JI; Noguchi K; Kondo T; Noguchi M Free Radic Biol Med; 2018 Dec; 129():537-547. PubMed ID: 30355525 [TBL] [Abstract][Full Text] [Related]
16. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways. Bijangi-Vishehsaraei K; Reza Saadatzadeh M; Wang H; Nguyen A; Kamocka MM; Cai W; Cohen-Gadol AA; Halum SL; Sarkaria JN; Pollok KE; Safa AR J Neurosurg; 2017 Dec; 127(6):1219-1230. PubMed ID: 28059653 [TBL] [Abstract][Full Text] [Related]
17. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma. Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735 [TBL] [Abstract][Full Text] [Related]
18. SK channel activation potentiates auranofin-induced cell death in glio- and neuroblastoma cells. Krabbendam IE; Honrath B; Bothof L; Silva-Pavez E; Huerta H; Peñaranda Fajardo NM; Dekker F; Schmidt M; Culmsee C; César Cárdenas J; Kruyt F; Dolga AM Biochem Pharmacol; 2020 Jan; 171():113714. PubMed ID: 31738894 [TBL] [Abstract][Full Text] [Related]